Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas

K. Takano; M. Kinoshita; H. Arita; Y. Okita; Y. Chiba; N. Kagawa; Y. Fujimoto; H. Kishima; Y. Kanemura; M. Nonaka; S. Nakajima; E. Shimosegawa; J. Hatazawa; N. Hashimoto; T. Yoshimine

doi:10.3174/ajnr.A4460

Abstract

BACKGROUND AND PURPOSE: Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection of malignant transformation. Although positron-emission tomography is considered valuable in the care of patients with gliomas, ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine have reportedly shown ambiguous results in terms of grading and prognostication. The present study compared the diagnostic and prognostic capabilities of diffusion tensor imaging, FDG, and ¹¹C-methionine PET in nonenhancing gliomas.

MATERIALS AND METHODS: Thirty-five consecutive newly diagnosed, histologically confirmed nonenhancing gliomas that underwent both FDG and ¹¹C-methionine PET were retrospectively investigated (23 grade II and 12 grade III gliomas). Apparent diffusion coefficient, fractional anisotropy, and tumor-to-normal tissue ratios of both FDG and ¹¹C-methionine PET were compared between grade II and III gliomas. Prognostic values of these parameters were also tested by using progression-free survival.

RESULTS: Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor2-to-normal tissue than grade II gliomas in ¹¹C-methionine (P = .013, P = .0017, respectively), but not in FDG-PET imaging. There was no significant difference in average ADC, minimum ADC, average fractional anisotropy, and maximum fractional anisotropy. ¹¹C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%). Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of <2.0 for ¹¹C-methionine PET and 18.6 ± 6.9 months in patients with maximum tumor-to-normal tissue ratio of >2.0 (P = .0044).

CONCLUSIONS: ¹¹C-methionine PET holds promise for World Health Organization grading and could offer a prognostic imaging biomarker for nonenhancing gliomas.

ABBREVIATIONS:

MET: ¹¹C-methionine
PFS: progression-free survival
T/N: tumor-to-normal tissue
T/N_ave: average tumor-to-normal tissue
T/N_max: maximum tumor-to-normal tissue

Gliomas are categorized from grade I to IV according to the World Health Organization classification, which is based on histopathologic findings.¹ Although molecular and genetic information is gaining importance,² therapeutic strategy is still heavily based on World Health Organization grading. Biopsy is occasionally chosen instead of surgical resection due to various factors such as tumor location, and the heterogeneous features of the tumor often complicate accurate diagnosis, leading to undergrading of the tumor.^3,4

MR imaging is one of the noninvasive methods for tumor grading and is now considered the criterion standard imaging procedure for glioma.⁵ Although contrast enhancement of the tumor is regarded as a hallmark of high-grade glioma, anaplastic tumors and even glioblastoma can lack contrast enhancement. Previous reports have shown that 32%–42% of nonenhancing gliomas are high-grade. In other words, as many as 92%–100% of nonenhancing gliomas are grade II or III gliomas.^{6⇓⇓⇓⇓–11} As a result, nonenhancing glioma contains various tumor grades ranging from grade II to IV. In the context of nonenhancing tumor, accurate preoperative diagnosis may change the initial management of the tumor, and if grade III is suspected, a more aggressive surgical resection, rather than biopsy, may be pursued. This treatment strategy poses a challenge to physicians to achieve a correct preoperative diagnosis and leads to a need for additional imaging modalities to visualize tumor characteristics. Although previous investigations have attempted to solve this problem by using various advanced MR imaging techniques such as diffusion tensor imaging, perfusion-weighted imaging, and MR spectroscopy,^6,7,9,12 the clinical significance of these methods remains controversial. In this context, positron-emission tomography is considered a promising imaging technique supplementing MR imaging in the care of patients with gliomas. Past investigations, however, have analyzed mixtures of both high- and low-grade gliomas for their analyses, leading to inconclusive results in terms of its usefulness in clinical practice. The most important question to be answered is the clinical impact of PET on nonenhancing gliomas, in which tumor grading is difficult using conventional MR imaging alone. Hence, the current investigation was conducted to test the hypothesis that PET could be useful for both radiologic tumor grading and prognostication of nonenhancing gliomas. More specifically, our aim was to test the hypothesis that ¹¹C-methionine (MET) PET not only has greater specificity and positive predictive power than ¹⁸F-fluorodeoxyglucose-PET for determination of grade in nonenhancing gliomas but also predicts progression-free survival in newly diagnosed nonenhancing gliomas receiving standard therapy. The results obtained from PET were further compared with apparent diffusion coefficient obtained by DTI.

Materials and Methods

Patients

Thirty-five patients with newly diagnosed, histologically confirmed nonenhancing supratentorial gliomas were retrospectively collected (18 men, 17 women; mean age, 39.9 ± 15.8 years; World Health Organization grade II, n = 23; grade III, n = 12). Four of the 23 grade II gliomas and 3 of the 12 grade III gliomas showed oligodendrocytic components. Histologic grading was performed according to the World Health Organization criteria after partial (<95% tumor removal) or total (≥95% tumor removal) resection of the lesion or stereotactic biopsy (total resection, n = 11; partial resection, n = 21; stereotactic biopsy, n = 3). Three patients with grade II gliomas and all patients with grade III gliomas received adjuvant therapy postoperatively, such as radiation therapy alone, radiation therapy with chemotherapy, or chemotherapy alone. Both FDG and MET PET were performed preoperatively except in 1 case, in which PET was performed 69 days after stereotactic biopsy. The mean duration of follow-up was 29.6 ± 18.1 months. “Tumor progression” was defined as either distinct enlargement of high-intensity lesions on T2 or fluid-attenuated inversion recovery imaging or the appearance of a contrast-enhancing lesion. “Progression-free survival” was defined as the duration between surgery and tumor progression. Detailed characteristics of patients are given in On-line Table 1. Use of clinical data was approved for research purposes by the local institutional review board.

PET Methods

PET studies were performed by using an Eminence-G (Shimadzu, Kyoto, Japan). Synthesis of MET was performed according to the method described by Berger et al,¹³ and MET was injected intravenously at a dose of 3 MBq/kg. Tracer accumulation was recorded for 12 minutes in 59 or 99 transaxial sections over the entire brain. Summed activity from 20 to 32 minutes after tracer injection was used for image reconstruction. For FDG-PET, after a 10-minute transmission scan, an amount of FDG determined in proportion to weight was injected intravenously (3.7 MBq/kg). Tracer accumulation was recorded in 3D mode for 12 minutes in 59 or 99 transaxial sections from the entire brain. Total activity from 45 to 57 minutes after tracer injection was used for image reconstruction. Both images were stored in 256 × 256 × 59 or 99 anisotropic voxels, with each voxel being 1 × 1 × 2.6 mm. The mean interval between preceding PET and an operation was 60.4 ± 68.8 days (range, −69 to 347 days).

MR Imaging

All patients were studied by using either a 1.5T or 3T MR imaging scanner within a week before the operation. T1-weighted imaging with gadolinium enhancement was used to select patients with nonenhancing gliomas. T2-weighted or FLAIR images were acquired in all cases for delineation of tumors. Diffusion tensor imaging was performed in all except 4 patients (21 with grade II glioma and 10 with grade III glioma) by using a 3T MR imaging scanner (Signa; GE Healthcare, Milwaukee, Wisconsin). Images were acquired by using a single-shot echo-planar imaging technique with TE = 80 and TR = 10,000. Diffusion gradient encoding in 25 directions with b=2000 s/mm² and an additional measurement without the diffusion gradient (b=0 s/mm²) were performed.¹⁴ A parallel imaging technique was used to record data with a 128 × 128 spatial resolution for a 260 × 260 mm FOV. Fifty sections were obtained, with a section thickness of 3 mm and no intersection gap. Apparent diffusion coefficient was processed by using the Diffusion Toolkit (TrackVis; http://www.trackvis.org/dtk/).

Image Fusion and Analysis

After all images had been obtained, PET images, ADC, and FA maps were all registered to T2 or FLAIR images by using VINCI image analysis software (http://www.nf.mpg.de/vinci/). Correct coregistration of images was visually confirmed. After image registration was complete, all image sets were converted to anisotropic images (256 × 256 × 59 or 99, 1 × 1 × 2.6 mm), enabling further analysis. For PET images, the standard uptake value of the contralateral tumor-unaffected gray matter in the axial plane at the level of the thalamus was averaged, and the derived value was used to normalize standard uptake value in a voxelwise manner, enabling reconstruction of tumor-to-normal tissue (T/N) ratio images. All datasets were exported to in-house software written in Matlab 7.14 (MathWorks, Natick, Massachusetts) for further analysis. High-intensity lesions delineated in T2 or FLAIR images were semiautomatically segmented in 3D by image-intensity threshold as voxels of interest. Average tumor-to-normal tissue (T/N_ave) and maximum tumor-to-normal tissue values (T/N_max) of FDG and MET PET, average ADC, and minimum ADC within the VOI were calculated (Fig 1 and On-line Fig 1). In particular, the same VOIs were applied to all 4 images. All values are reported as mean ± SD.

Fig 1.

Schematic overview of the image-analysis process. High-intensity lesions on T2/FLAIR imaging were semiautomatically segmented in 3D by an image-intensity threshold. The segmented voxels of interest were applied to registered PET images and ADC fractional anisotropy maps, followed by calculation of the average and maximum or minimal values of each parameter within the VOI.

Statistical Analysis

Statistical analysis was performed by using JMP Version 10 software (SAS Institute, Cary, North Carolina). A threshold level of .05 was established for statistical significance. The Mann-Whitney U test was used for group comparisons. Receiver operating characteristic analysis was performed to compare the performance of each imaging parameter in distinguishing grade III from grade II gliomas. The duration of progression-free survival (PFS; reported as median ± standard error) was analyzed by Kaplan-Meier curves, and log-rank testing was performed to determine the statistical significance of any observed differences in PFS between groups. Overall survival was not analyzed because most patients have not yet reached this end point.

Results

FDG Uptake is Not Statistically Different between Grade II and III Nonenhancing Gliomas

The T/N_ave of FDG-PET for grade II and III gliomas was 0.68 ± 0.28 and 0.69 ± 0.06, and T/N_max was 1.28 ± 0.33 and 1.25 ± 0.15, respectively (Fig 2 and Table 1). These differences were not significant (P = .11 and P = .72, respectively). Receiver operating characteristic analysis showed that the T/N_ave of FDG-PET performed best at a cutoff value of 0.61, with an area under the curve of 0.67 for discriminating grade III from grade II gliomas (Table 2).

Fig 2.

T/N_ave (A) and T/N_max (B) of FDG-PET in patients with grade II and III gliomas. No significant difference was seen between grade II and III gliomas (P = .11 and 0.72, respectively).

View this table:

Table 1:

Various imaging modalities and tumor grade

View this table:

Table 2:

ROC analysis to discriminate tumor grade

MET Uptake Was Statistically Significantly Higher in Grade III Nonenhancing Gliomas Than in Grade II Nonenhancing Gliomas

The T/N_ave of MET PET for grade II and III gliomas was 1.12 ± 0.18 and 1.31 ± 0.21, and T/N_max was 1.91 ± 0.62 and 2.69 ± 0.66, respectively (Fig 3 and Table 1). Grade III gliomas showed significantly higher MET T/N_ave and T/N_max than grade II gliomas (P = .013, P = .0017, respectively). Receiver operating characteristic analysis showed that the T/N_max of MET PET performed best at a cutoff value of 2.0, with an area under the curve of 0.83 for discriminating grade III from grade II gliomas (Fig 4 and Table 2).

Fig 3.

T/N_ave (A) and T/N_max (B) of MET PET in patients with grade II and III gliomas. Grade III gliomas show significantly higher T/N_ave and T/N_max than grade II gliomas (P = .013, P = .0017, respectively).

Fig 4.

Receiver operating characteristic analysis of MET PET and FDG-PET T/N_max was used for discriminating grade III from grade II gliomas. The area under the curve was 0.83, and the sensitivity and specificity were 83.3% and 73.9% at a cutoff T/N_max of 2.0 for MET PET. FDG-PET was unable to discriminate grade III glioma from grade II.

ADC Did Not Show a Statistically Significant Difference between Grade II and III Nonenhancing Gliomas

Average ADCs for grade II and III gliomas were 1.09 ± 0.25 and 0.92 ± 0.22, and minimum ADCs were 0.18 ± 0.26 and 0.18 ± 0.23, respectively (Table 1). These differences were not statistically significant (P = .13 and P = .82, respectively). Receiver operating characteristic analysis based on ADC further supported these findings (Table 2).

MET PET Is Prognostic for PFS in Nonenhancing Gliomas

The median PFS for patients with grade II gliomas was 64.2 ± 6.0 months (95% CI, 20.6–64.2 months), while the median PFS for patients with grade III glioma was 36.3 ± 4.9 months (95% CI, 4.5 months not available). No difference in PFS was evident between grade II and III gliomas (P = .32) (Fig 5A).

Fig 5.

Progression-free survival analysis by tumor grade and MET PET results. Progression-free survival is shown in Kaplan-Meier curves according to tumor grade (A). Patients with T/N_max of <2.0 showed prolonged progression-free survival compared with those with T/N_max of >2.0 (B, P = .006). This was also true when the analysis was restricted to patients who received no adjuvant therapy (C, P = .004).

On the other hand, median PFS was 64.2 ± 6.3 months (95% CI, 34.0–64.2 months) for patients with T/N_max of <2.0 for MET PET (n = 19) and 18.8 ± 4.0 months (95% CI, 7.4–37.0 months) for patients with T/N_max of >2.0 (n = 16). There was a statistically significant difference for the PFS between these groups (P = .006) (Fig 5B).

Because some patients underwent adjuvant therapy, which could affect PFS, such as radiation therapy alone, radiation therapy with chemotherapy, or chemotherapy alone, further analysis was performed for patients who did not receive any adjuvant therapy (n = 20, all grade II gliomas). Median PFS was 64.2 ± 7.2 months (95% CI, 34.0–64.2 months) for patients with T/N_max of <2.0 for MET PET (n = 15) and 18.6 ± 6.9 months (95% CI, 7.4–37.0 months) for patients with T/N_max of >2.0 (n = 5). This difference was statistically significant (P = .0044) (Fig 5C). On the other hand, MET PET was not prognostic among patients who received adjuvant therapy (P = .37). The above findings were confirmed even when PFS was calculated as the duration between PET examination and tumor progression (On-line Fig 2). Finally, MET PET was prognostic among patients with grade II gliomas but not among patients with grade III gliomas (P = .016 and P = .22, respectively). Detailed data are shown in On-line Table 2.

Discussion

The utility of FDG-PET in glioma was reported in 1982 by Di Chiro et al,¹⁵ followed by many reports confirming that FDG-PET is indeed useful for detection, grading, and prognostication for gliomas.^{8,16⇓⇓⇓⇓⇓⇓–23} On the other hand, MET PET was first reported in 1983 by Bergström et al²⁴ as a useful imaging technique to delineate glioma. Because MET PET has a low normal cortical uptake and high uptake in gliomas, this method has been considered superior to FDG-PET for delineation of the lesion.^25⇓–27

However, reports on grading and prognostication of gliomas by MET PET have been conflicting. Some reports have claimed that FDG-PET is better for grading and prognostication than MET PET,^{26,28⇓–30} while others have claimed otherwise.^{27,31⇓–33} In theory, accumulation of MET is influenced not only by specific carrier-mediated uptake but also by passive diffusion in areas with a disrupted blood-brain barrier,^34⇓–36 while background normal cortical uptake of the tracer markedly interferes with accumulation of FDG in brain tumors. One possible reason for the above-mentioned controversy could be the patient populations analyzed in those studies, in which both enhancing and nonenhancing tumors were analyzed together.^{26⇓⇓⇓⇓⇓⇓–33} Moreover, from a clinical point of view, because contrast enhancement is one of the hallmarks of high-grade tumor, the most important clinical question to be answered would be the tumor grade in nonenhancing tumors, in which tumor grading is difficult by using conventional MR imaging alone.

When analysis was restricted to nonenhancing glioma by using a semiautomatic T2/FLAIR-based VOI segmentation, the presented results clearly proved the superb performance of MET PET for tumor grading (Figs 2 ⇑–4 and Tables 1 and 2). Receiver operating characteristic analysis further revealed that T/N_max of MET PET was most efficient in extracting grade III gliomas among nonenhancing gliomas, with an area under the curve of 0.83 (Fig 4 and Table 2). These findings imply that MET PET could be a valuable noninvasive radiologic tool for making significant clinical judgments for nonenhancing gliomas because preoperative identification of grade III gliomas would justify clinicians putting those patients into radical treatment rather than biopsy or observation of the tumor. The considerable overlap of MET T/N between grade II and III gliomas (Fig 3), however, mandates cautious interpretation of MET PET to supplement conventional MR imaging for grading of nonenhancing gliomas. On the other hand, FDG-PET was not useful in this respect (Figs 2 ⇑–4 and Tables 1 and 2).

Similar to FDG-PET, ADC obtained from DTI was also incompetent to distinguish both grade II and III nonenhancing gliomas (Tables 1 and 2). Because glioma grading by using DTI can be heavily affected by the method used for VOI or ROI design,^7,9,37,38 it could be that T2/FLAIR-based semiautomatic MR imaging intensity-based VOI segmentation was not sensitive for this purpose. Further investigation is indeed necessary to clarify the impact of the method used for VOI segmentation on analysis of both PET and MR imaging.

Finally, no significant difference in PFS was seen between grade II and III gliomas in our cohort. In the Long-Term Efficacy of Early versus Delayed Radiotherapy for Low-Grade Astrocytoma and Oligodendroglioma in Adults trial, a randomized controlled trial comparing early-versus-delayed radiation therapy for low-grade gliomas, median PFS was 5.3 years in the early radiation therapy group and 3.4 years in the delayed group.³⁹ Among grade III gliomas, on the other hand, median PFS was reported as 7.6–36 months for patients treated by radiation therapy and chemotherapy and 13–18 months for patients treated by using radiation therapy alone.^{40⇓⇓⇓⇓–45} Considering that all except 3 patients with grade II gliomas were followed postoperatively with careful observation alone and that all except 1 patient with a grade III glioma were treated by using both radiation therapy and chemotherapy, PFS of our cohort for grade II and III gliomas seems to be in range with past studies. Early intervention by adjuvant therapy against grade III gliomas could have prolonged PFS of patients with grade III gliomas to a similar level of grade II gliomas. More important, MET PET was prognostic of PFS not only in all patients with nonenhancing gliomas but also in patients without adjuvant therapy; this outcome makes MET PET a potential prognostic imaging biomarker for nonenhancing gliomas.

Limitations of our study should also be noted. The present study compared radiologic with pathologic tumor grading under the assumption that correct pathologic diagnosis was obtained. Because there was only 1 patient in this cohort who was diagnosed as having grade II glioma by biopsy, it is highly unlikely that tissue-sampling error has occurred in our analysis. Possible pathologic undergrading, however, should always be considered, even if the tumor has been largely resected. Another limitation is in PFS analysis. Many potentially confounding factors influence PFS, such as age, extent of removal, histopathologic subtype, and molecular prognostic biomarkers, as well as adjuvant therapy. Because it has become clear that grade II and grade III gliomas exhibit different clinical courses according to their molecular subtypes,^46,47 future studies should incorporate this information when conducting survival analysis on the basis of radiologic findings. Finally, prognostic values of imaging parameters should be analyzed not only with PFS but also with overall survival, which requires further future investigation.

Conclusions

MET PET holds promise as a noninvasive World Health Organization grading technique and prognostic imaging biomarker, offering valuable information in determining treatment strategy for nonenhancing gliomas, while FDG-PET or ADC offer little diagnostic and prognostic value.

Footnotes

Disclosures: Manbu Kinoshita—RELATED: Grant: Aichi Cancer Research Foundation, SENSIN Medical Research Foundation,* Life Science Foundation of Japan,* Japanese Foundation for Multidisciplinary Treatment of Cancer and Japan Society for the Promotion of Science KAKENHI (25462256).* Koji Takano—UNRELATED: Grants/Grants Pending: KAKENHI grant No. 26670642. Haruhiko Kishima—UNRELATED: Grants/Grants Pending: Grants-in-Aid for Scientific Research (T 26462207) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Yonehiro Kanemura—UNRELATED: Grants/Grants Pending: Kaneka Corp, Japan,* Comments: This is a research grant for stem cell technology. The author declares no conflicts of interest associated with this article; Patents (planned, pending, or issued): Kaneka Corp, Japan,* Comments: This is a patent for stem cell technology. The author declares no conflicts of interest associated with this article. *Money paid to the institution.
This investigation was supported by the Aichi Cancer Research Foundation, the SENSIN Medical Research Foundation, the Life Science Foundation of Japan, the Japanese Foundation for Multidisciplinary Treatment of Cancer, and Japan Society for the Promotion of Science KAKENHI (25462256).

Indicates open access to non-subscribers at www.ajnr.org

References

1.↵
2. Louis DN,
3. Ohgaki H,
4. Wiestler OD, et al
. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109 doi:10.1007/s00401-007-0243-4 pmid:17618441
CrossRef PubMed
2.↵
2. Marumoto T,
3. Saya H
. Molecular biology of glioma. Adv Exp Med Biol 2012;746:2–11 doi:10.1007/978-1-4614-3146-6_1 pmid:22639155
CrossRef PubMed
3.↵
2. Shapiro JR,
3. Yung WK,
4. Shapiro WR
. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 1981;41:2349–59 pmid:7016313
Abstract/FREE Full Text
4.↵
2. Lasocki A,
3. Tsui A,
4. Tacey MA, et al
. MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288
Abstract/FREE Full Text
5.↵
2. Chen W,
3. Silverman DH
. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240–50 doi:10.1053/j.semnuclmed.2008.02.005 pmid:18514080
CrossRef PubMed
6.↵
2. Batra A,
3. Tripathi RP,
4. Singh AK
. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol 2004;48:324–32 doi:10.1111/j.0004-8461.2004.01315.x pmid:15344981
CrossRef PubMed
7.↵
2. Fan GG,
3. Deng QL,
4. Wu ZH, et al
. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 2006;79:652–58 doi:10.1259/bjr/25349497 pmid:16641420
Abstract/FREE Full Text
8.↵
2. Barker FG 2nd.,
3. Chang SM,
4. Valk PE, et al
. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115–26 pmid:8988735
CrossRef PubMed
9.↵
2. Liu X,
3. Tian W,
4. Kolar B, et al
. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol 2011;13:447–55 doi:10.1093/neuonc/noq197 pmid:21297125
Abstract/FREE Full Text
10.↵
2. Scott JN,
3. Brasher PM,
4. Sevick RJ, et al
. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947–49 doi:10.1212/WNL.59.6.947 pmid:12297589
Abstract/FREE Full Text
11.↵
2. Ginsberg LE,
3. Fuller GN,
4. Hashmi M, et al
. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–40 doi:10.1016/S0090-3019(97)00360-1 pmid:9537664
CrossRef PubMed
12.↵
2. Maia AC Jr.,
3. Malheiros SM,
4. da Rocha AJ, et al
. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83 pmid:15814920
Abstract/FREE Full Text
13.↵
2. Berger G,
3. Maziere M,
4. Knipper R, et al
. Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 1979;30:393–99 doi:10.1016/0020-708X(79)90049-8 pmid:478664
CrossRef PubMed
14.↵
2. Yoshiura T,
3. Mihara F,
4. Tanaka A, et al
. High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease. Neuroimage 2003;20:413–19 doi:10.1016/S1053-8119(03)00342-2 pmid:14527601
CrossRef PubMed
15.↵
2. Di Chiro G,
3. DeLaPaz RL,
4. Brooks RA, et al
. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–29 doi:10.1212/WNL.32.12.1323 pmid:6983044
Abstract/FREE Full Text
16.↵
2. Ishikawa M,
3. Kikuchi H,
4. Miyatake S, et al
. Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28–33 doi:10.1227/00006123-199307000-00004 pmid:8355844
CrossRef PubMed
17.↵
2. De Witte O,
3. Levivier M,
4. Violon P, et al
. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470–76; discussion 476–77 doi:10.1097/00006123-199609000-00007 pmid:8875476
CrossRef PubMed
18.↵
2. Patronas NJ,
3. Di Chiro G,
4. Kufta C, et al
. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816–22 doi:10.3171/jns.1985.62.6.0816 pmid:2987440
CrossRef PubMed
19.↵
2. Alavi JB,
3. Alavi A,
4. Chawluk J, et al
. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988;62:1074–78 pmid:3261622
CrossRef PubMed
20.↵
2. Goldman S,
3. Levivier M,
4. Pirotte B, et al
. Regional glucose metabolism and histopathology of gliomas: a study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106 pmid:8780549
CrossRef PubMed
21.↵
2. Pirotte B,
3. Goldman S,
4. Bidaut LM, et al
. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien) 1995;134:79–82 doi:10.1007/BF01428509 pmid:7668134
CrossRef PubMed
22.↵
2. Ishizu K,
3. Nishizawa S,
4. Yonekura Y, et al
. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104–09 pmid:8014665
Abstract/FREE Full Text
23.↵
2. Padma MV,
3. Said S,
4. Jacobs M, et al
. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–37 doi:10.1023/A:1025665820001 pmid:14558598
CrossRef PubMed
24.↵
2. Bergström M,
3. Collins VP,
4. Ehrin E, et al
. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062–66 doi:10.1097/00004728-198312000-00022 pmid:6415134
CrossRef PubMed
25.↵
2. Kato T,
3. Shinoda J,
4. Nakayama N, et al
. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176–82 doi:10.3174/ajnr.A1008 pmid:18388218
Abstract/FREE Full Text
26.↵
2. Borbély K,
3. Nyáry I,
4. Tóth M, et al
. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85–94 doi:10.1016/j.jns.2006.02.015 pmid:16603193
CrossRef PubMed
27.↵
2. Voges J,
3. Herholz K,
4. Hölzer T, et al
. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69(1–4 pt 2):129–35 pmid:9711745
CrossRef PubMed
28.↵
2. Ogawa T,
3. Inugami A,
4. Hatazawa J, et al
. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345–53 pmid:8938309
Abstract
29.↵
2. Singhal T,
3. Narayanan TK,
4. Jain V, et al
. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1–18 doi:10.1007/s11307-007-0115-2 pmid:17957408
CrossRef PubMed
30.↵
2. Utriainen M,
3. Metsähonkala L,
4. Salmi TT, et al
. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002;95:1376–86 doi:10.1002/cncr.10798 pmid:12216107
CrossRef PubMed
31.↵
2. Derlon JM,
3. Chapon F,
4. Noël MH, et al
. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778–87 doi:10.1007/s002590000260 pmid:10952489
CrossRef PubMed
32.↵
2. Kaschten B,
3. Stevenaert A,
4. Sadzot B, et al
. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85 pmid:9591574
Abstract/FREE Full Text
33.↵
2. Singhal T,
3. Narayanan TK,
4. Jacobs MP, et al
. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709–15 doi:10.2967/jnumed.111.102533 pmid:23055534
Abstract/FREE Full Text
34.↵
2. Bergström M,
3. Lundqvist H,
4. Ericson K, et al
. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987;28:225–29 doi:10.1177/028418518702800301 pmid:2958026
Abstract/FREE Full Text
35.↵
2. Roelcke U,
3. Radü E,
4. Ametamey S, et al
. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996;27:163–71 pmid:8699239
PubMed
36.↵
2. Jager PL,
3. Vaalburg W,
4. Pruim J, et al
. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45 pmid:11337520
Abstract/FREE Full Text
37.↵
2. Kinoshita M,
3. Hashimoto N,
4. Goto T, et al
. Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage 2008;43:29–35 doi:10.1016/j.neuroimage.2008.06.041 pmid:18672074
CrossRef PubMed
38.↵
2. LaViolette PS,
3. Mickevicius NJ,
4. Cochran EJ, et al
. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol 2014;16:1599–606 doi:10.1093/neuonc/nou142 pmid:25059209
Abstract/FREE Full Text
39.↵
2. van den Bent MJ,
3. Afra D,
4. de Witte O, et al
. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985–90 doi:10.1016/S0140-6736(05)67070-5 pmid:16168780
CrossRef PubMed
40.↵
2. Cairncross G,
3. Berkey B,
4. Shaw E, et al
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707–14 doi:10.1200/JCO.2005.04.3414 pmid:16782910
Abstract/FREE Full Text
41.↵
2. Gilbert MR,
3. Friedman HS,
4. Kuttesch JF, et al
. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 2002;4:261–67 doi:10.1093/neuonc/4.4.261 pmid:12356356
Abstract/FREE Full Text
42.↵
2. Shibui S,
3. Narita Y,
4. Mizusawa J, et al
. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013;71:511–21 doi:10.1007/s00280-012-2041-5 pmid:23228988
CrossRef PubMed
43.↵
2. Brandes AA,
3. Nicolardi L,
4. Tosoni A, et al
. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006;8:253–60 doi:10.1215/15228517-2006-005 pmid:16723632
Abstract/FREE Full Text
44.↵
2. van den Bent MJ,
3. Carpentier AF,
4. Brandes AA, et al
. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–22 doi:10.1200/JCO.2005.04.6078 pmid:16782911
Abstract/FREE Full Text
45.↵
2. Wick W,
3. Hartmann C,
4. Engel C, et al
. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874–80 doi:10.1200/JCO.2009.23.6497 pmid:19901110
Abstract/FREE Full Text
46.↵
2. Cairncross G,
3. Wang M,
4. Shaw E, et al
. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 doi:10.1200/JCO.2012.43.2674 pmid:23071247
Abstract/FREE Full Text
47.↵
2. Suzuki H,
3. Aoki K,
4. Chiba K, et al
. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015;47:458–68 doi:10.1038/ng.3273 pmid:25848751
CrossRef PubMed

Received March 2, 2015.
Accepted after revision May 7, 2015.

View Abstract

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

More in this TOC Section

Show more ADULT BRAIN

[1] 1.↵

Louis DN,
Ohgaki H,
Wiestler OD, et al
. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109 doi:10.1007/s00401-007-0243-4 pmid:17618441
CrossRef PubMed

[3] Louis DN,

[4] Ohgaki H,

[5] Wiestler OD, et al

[6] 2.↵

Marumoto T,
Saya H
. Molecular biology of glioma. Adv Exp Med Biol 2012;746:2–11 doi:10.1007/978-1-4614-3146-6_1 pmid:22639155
CrossRef PubMed

[8] Marumoto T,

[9] Saya H

[10] 3.↵

Shapiro JR,
Yung WK,
Shapiro WR
. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 1981;41:2349–59 pmid:7016313
Abstract/FREE Full Text

[12] Shapiro JR,

[13] Yung WK,

[14] Shapiro WR

[15] 4.↵

Lasocki A,
Tsui A,
Tacey MA, et al
. MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288
Abstract/FREE Full Text

[17] Lasocki A,

[18] Tsui A,

[19] Tacey MA, et al

[20] 5.↵

Chen W,
Silverman DH
. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240–50 doi:10.1053/j.semnuclmed.2008.02.005 pmid:18514080
CrossRef PubMed

[22] Chen W,

[23] Silverman DH

[24] 6.↵

Batra A,
Tripathi RP,
Singh AK
. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol 2004;48:324–32 doi:10.1111/j.0004-8461.2004.01315.x pmid:15344981
CrossRef PubMed

[26] Batra A,

[27] Tripathi RP,

[28] Singh AK

[29] 7.↵

Fan GG,
Deng QL,
Wu ZH, et al
. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 2006;79:652–58 doi:10.1259/bjr/25349497 pmid:16641420
Abstract/FREE Full Text

[31] Fan GG,

[32] Deng QL,

[33] Wu ZH, et al

[34] 8.↵

Barker FG 2nd.,
Chang SM,
Valk PE, et al
. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115–26 pmid:8988735
CrossRef PubMed

[36] Barker FG 2nd.,

[37] Chang SM,

[38] Valk PE, et al

[39] 9.↵

Liu X,
Tian W,
Kolar B, et al
. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol 2011;13:447–55 doi:10.1093/neuonc/noq197 pmid:21297125
Abstract/FREE Full Text

[41] Liu X,

[42] Tian W,

[43] Kolar B, et al

[44] 10.↵

Scott JN,
Brasher PM,
Sevick RJ, et al
. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947–49 doi:10.1212/WNL.59.6.947 pmid:12297589
Abstract/FREE Full Text

[46] Scott JN,

[47] Brasher PM,

[48] Sevick RJ, et al

[49] 11.↵

Ginsberg LE,
Fuller GN,
Hashmi M, et al
. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–40 doi:10.1016/S0090-3019(97)00360-1 pmid:9537664
CrossRef PubMed

[51] Ginsberg LE,

[52] Fuller GN,

[53] Hashmi M, et al

[54] 12.↵

Maia AC Jr.,
Malheiros SM,
da Rocha AJ, et al
. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83 pmid:15814920
Abstract/FREE Full Text

[56] Maia AC Jr.,

[57] Malheiros SM,

[58] da Rocha AJ, et al

[59] 13.↵

Berger G,
Maziere M,
Knipper R, et al
. Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 1979;30:393–99 doi:10.1016/0020-708X(79)90049-8 pmid:478664
CrossRef PubMed

[61] Berger G,

[62] Maziere M,

[63] Knipper R, et al

[64] 14.↵

Yoshiura T,
Mihara F,
Tanaka A, et al
. High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease. Neuroimage 2003;20:413–19 doi:10.1016/S1053-8119(03)00342-2 pmid:14527601
CrossRef PubMed

[66] Yoshiura T,

[67] Mihara F,

[68] Tanaka A, et al

[69] 15.↵

Di Chiro G,
DeLaPaz RL,
Brooks RA, et al
. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–29 doi:10.1212/WNL.32.12.1323 pmid:6983044
Abstract/FREE Full Text

[71] Di Chiro G,

[72] DeLaPaz RL,

[73] Brooks RA, et al

[74] 16.↵

Ishikawa M,
Kikuchi H,
Miyatake S, et al
. Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28–33 doi:10.1227/00006123-199307000-00004 pmid:8355844
CrossRef PubMed

[76] Ishikawa M,

[77] Kikuchi H,

[78] Miyatake S, et al

[79] 17.↵

De Witte O,
Levivier M,
Violon P, et al
. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470–76; discussion 476–77 doi:10.1097/00006123-199609000-00007 pmid:8875476
CrossRef PubMed

[81] De Witte O,

[82] Levivier M,

[83] Violon P, et al

[84] 18.↵

Patronas NJ,
Di Chiro G,
Kufta C, et al
. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816–22 doi:10.3171/jns.1985.62.6.0816 pmid:2987440
CrossRef PubMed

[86] Patronas NJ,

[87] Di Chiro G,

[88] Kufta C, et al

[89] 19.↵

Alavi JB,
Alavi A,
Chawluk J, et al
. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988;62:1074–78 pmid:3261622
CrossRef PubMed

[91] Alavi JB,

[92] Alavi A,

[93] Chawluk J, et al

[94] 20.↵

Goldman S,
Levivier M,
Pirotte B, et al
. Regional glucose metabolism and histopathology of gliomas: a study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106 pmid:8780549
CrossRef PubMed

[96] Goldman S,

[97] Levivier M,

[98] Pirotte B, et al

[99] 21.↵

Pirotte B,
Goldman S,
Bidaut LM, et al
. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien) 1995;134:79–82 doi:10.1007/BF01428509 pmid:7668134
CrossRef PubMed

[101] Pirotte B,

[102] Goldman S,

[103] Bidaut LM, et al

[104] 22.↵

Ishizu K,
Nishizawa S,
Yonekura Y, et al
. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104–09 pmid:8014665
Abstract/FREE Full Text

[106] Ishizu K,

[107] Nishizawa S,

[108] Yonekura Y, et al

[109] 23.↵

Padma MV,
Said S,
Jacobs M, et al
. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–37 doi:10.1023/A:1025665820001 pmid:14558598
CrossRef PubMed

[111] Padma MV,

[112] Said S,

[113] Jacobs M, et al

[114] 24.↵

Bergström M,
Collins VP,
Ehrin E, et al
. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062–66 doi:10.1097/00004728-198312000-00022 pmid:6415134
CrossRef PubMed

[116] Bergström M,

[117] Collins VP,

[118] Ehrin E, et al

[119] 25.↵

Kato T,
Shinoda J,
Nakayama N, et al
. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176–82 doi:10.3174/ajnr.A1008 pmid:18388218
Abstract/FREE Full Text

[121] Kato T,

[122] Shinoda J,

[123] Nakayama N, et al

[124] 26.↵

Borbély K,
Nyáry I,
Tóth M, et al
. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85–94 doi:10.1016/j.jns.2006.02.015 pmid:16603193
CrossRef PubMed

[126] Borbély K,

[127] Nyáry I,

[128] Tóth M, et al

[129] 27.↵

Voges J,
Herholz K,
Hölzer T, et al
. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69(1–4 pt 2):129–35 pmid:9711745
CrossRef PubMed

[131] Voges J,

[132] Herholz K,

[133] Hölzer T, et al

[134] 28.↵

Ogawa T,
Inugami A,
Hatazawa J, et al
. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345–53 pmid:8938309
Abstract

[136] Ogawa T,

[137] Inugami A,

[138] Hatazawa J, et al

[139] 29.↵

Singhal T,
Narayanan TK,
Jain V, et al
. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1–18 doi:10.1007/s11307-007-0115-2 pmid:17957408
CrossRef PubMed

[141] Singhal T,

[142] Narayanan TK,

[143] Jain V, et al

[144] 30.↵

Utriainen M,
Metsähonkala L,
Salmi TT, et al
. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002;95:1376–86 doi:10.1002/cncr.10798 pmid:12216107
CrossRef PubMed

[146] Utriainen M,

[147] Metsähonkala L,

[148] Salmi TT, et al

[149] 31.↵

Derlon JM,
Chapon F,
Noël MH, et al
. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778–87 doi:10.1007/s002590000260 pmid:10952489
CrossRef PubMed

[151] Derlon JM,

[152] Chapon F,

[153] Noël MH, et al

[154] 32.↵

Kaschten B,
Stevenaert A,
Sadzot B, et al
. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85 pmid:9591574
Abstract/FREE Full Text

[156] Kaschten B,

[157] Stevenaert A,

[158] Sadzot B, et al

[159] 33.↵

Singhal T,
Narayanan TK,
Jacobs MP, et al
. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709–15 doi:10.2967/jnumed.111.102533 pmid:23055534
Abstract/FREE Full Text

[161] Singhal T,

[162] Narayanan TK,

[163] Jacobs MP, et al

[164] 34.↵

Bergström M,
Lundqvist H,
Ericson K, et al
. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987;28:225–29 doi:10.1177/028418518702800301 pmid:2958026
Abstract/FREE Full Text

[166] Bergström M,

[167] Lundqvist H,

[168] Ericson K, et al

[169] 35.↵

Roelcke U,
Radü E,
Ametamey S, et al
. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996;27:163–71 pmid:8699239
PubMed

[171] Roelcke U,

[172] Radü E,

[173] Ametamey S, et al

[174] 36.↵

Jager PL,
Vaalburg W,
Pruim J, et al
. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45 pmid:11337520
Abstract/FREE Full Text

[176] Jager PL,

[177] Vaalburg W,

[178] Pruim J, et al

[179] 37.↵

Kinoshita M,
Hashimoto N,
Goto T, et al
. Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage 2008;43:29–35 doi:10.1016/j.neuroimage.2008.06.041 pmid:18672074
CrossRef PubMed

[181] Kinoshita M,

[182] Hashimoto N,

[183] Goto T, et al

[184] 38.↵

LaViolette PS,
Mickevicius NJ,
Cochran EJ, et al
. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol 2014;16:1599–606 doi:10.1093/neuonc/nou142 pmid:25059209
Abstract/FREE Full Text

[186] LaViolette PS,

[187] Mickevicius NJ,

[188] Cochran EJ, et al

[189] 39.↵

van den Bent MJ,
Afra D,
de Witte O, et al
. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985–90 doi:10.1016/S0140-6736(05)67070-5 pmid:16168780
CrossRef PubMed

[191] van den Bent MJ,

[192] Afra D,

[193] de Witte O, et al

[194] 40.↵

Cairncross G,
Berkey B,
Shaw E, et al
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707–14 doi:10.1200/JCO.2005.04.3414 pmid:16782910
Abstract/FREE Full Text

[196] Cairncross G,

[197] Berkey B,

[198] Shaw E, et al

[199] 41.↵

Gilbert MR,
Friedman HS,
Kuttesch JF, et al
. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 2002;4:261–67 doi:10.1093/neuonc/4.4.261 pmid:12356356
Abstract/FREE Full Text

[201] Gilbert MR,

[202] Friedman HS,

[203] Kuttesch JF, et al

[204] 42.↵

Shibui S,
Narita Y,
Mizusawa J, et al
. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013;71:511–21 doi:10.1007/s00280-012-2041-5 pmid:23228988
CrossRef PubMed

[206] Shibui S,

[207] Narita Y,

[208] Mizusawa J, et al

[209] 43.↵

Brandes AA,
Nicolardi L,
Tosoni A, et al
. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006;8:253–60 doi:10.1215/15228517-2006-005 pmid:16723632
Abstract/FREE Full Text

[211] Brandes AA,

[212] Nicolardi L,

[213] Tosoni A, et al

[214] 44.↵

van den Bent MJ,
Carpentier AF,
Brandes AA, et al
. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–22 doi:10.1200/JCO.2005.04.6078 pmid:16782911
Abstract/FREE Full Text

[216] van den Bent MJ,

[217] Carpentier AF,

[218] Brandes AA, et al

[219] 45.↵

Wick W,
Hartmann C,
Engel C, et al
. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874–80 doi:10.1200/JCO.2009.23.6497 pmid:19901110
Abstract/FREE Full Text

[221] Wick W,

[222] Hartmann C,

[223] Engel C, et al

[224] 46.↵

Cairncross G,
Wang M,
Shaw E, et al
. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 doi:10.1200/JCO.2012.43.2674 pmid:23071247
Abstract/FREE Full Text

[226] Cairncross G,

[227] Wang M,

[228] Shaw E, et al

[229] 47.↵

Suzuki H,
Aoki K,
Chiba K, et al
. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015;47:458–68 doi:10.1038/ng.3273 pmid:25848751
CrossRef PubMed

[231] Suzuki H,

[232] Aoki K,

[233] Chiba K, et al

Main menu

User menu

Search

American Journal of Neuroradiology

Diagnostic and Prognostic Value of ¹¹C-Methionine PET for Nonenhancing Gliomas

Abstract

ABBREVIATIONS:

Materials and Methods

Patients

PET Methods

MR Imaging

Image Fusion and Analysis

Statistical Analysis

Results

FDG Uptake is Not Statistically Different between Grade II and III Nonenhancing Gliomas

MET Uptake Was Statistically Significantly Higher in Grade III Nonenhancing Gliomas Than in Grade II Nonenhancing Gliomas

ADC Did Not Show a Statistically Significant Difference between Grade II and III Nonenhancing Gliomas

MET PET Is Prognostic for PFS in Nonenhancing Gliomas

Discussion

Conclusions

Footnotes

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology

Main menu

User menu

Search

Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas

Abstract

ABBREVIATIONS:

Materials and Methods

Patients

PET Methods

MR Imaging

Image Fusion and Analysis

Statistical Analysis

Results

FDG Uptake is Not Statistically Different between Grade II and III Nonenhancing Gliomas

MET Uptake Was Statistically Significantly Higher in Grade III Nonenhancing Gliomas Than in Grade II Nonenhancing Gliomas

ADC Did Not Show a Statistically Significant Difference between Grade II and III Nonenhancing Gliomas

MET PET Is Prognostic for PFS in Nonenhancing Gliomas

Discussion

Conclusions

Footnotes

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology

Diagnostic and Prognostic Value of ¹¹C-Methionine PET for Nonenhancing Gliomas